BIO-KOREA
13.5.2020 06:36:05 CEST | Business Wire | Press release
The BIO KOREA Organizing Committee announced it will hold the BIO KOREA 2020 International Convention scheduled for May 18–23 as an online convention instead of an in-person event for this year.
The decision was based on the impact of COVID-19, the safety of the attendees and global health recommendations regarding large, in-person gatherings.
BIO KOREA 2020 Online Convention
- Date: May 18 09:00 to 23 18:00 (KST)
- Point of Access: www.biokorea.org
- Program: Online Business Forum with Partnering, Virtual Exhibition, e-Conference, Invest Fair, Job Fair
Online Business Forum with Partnering
BIO KOREA 2020 Online Convention will focus on the virtual collaboration with its Partnering system allowing attendees to schedule virtual meetings to maximize their business development and licensing potential. International participation continues to grow. Numerous companies from 20+ countries are already joined and expected to showcase their advanced technologies at BIO KOREA 2020.
Definitely expecting to be a place where various kinds of discussion will be held, with Korean companies as not just the companies which are leading bio industry in Korea such as LG Chem Life Science, Samsung Biologics, Celltrion, and Hanmi Pharmaceuticals, etc., also promising SMEs like Organoid Science, YBRAIN, and Amyloid Solution are attending to foster their business. And 24-hour meeting slots will let strengthen your digital network across time zones.
Virtual Exhibition
The new format includes Virtual Exhibition where has set to show the cutting-edge technologies and products of exhibitors in various ways such as Digital Scan, Animation, 360° VR, and so on. 350+ exhibitors, from start-up to the global enterprise, will be at BIO KOREA's virtual exhibition and also there will be COVID-19 Special Zone to introduce South Korea's effective diagnostic tests, high-tech medical technology, and protocols.
e-Conference
The conference of BIO KOREA will also come with the online format under the theme of “A New Paradigm in the Age of Data Science” including expert-level content focused on the most pressing industry topics including COVID-19, Vaccine, Alzheimer’s Disease, Electroceutical, Digital Pathology, Digital Therapeutics, AI (Artificial Intelligence). BIO KOREA 2020’s e-Conference, covering 13 topics with 90+ speakers, will bring the most up-to-date conversations in biopharma to your home office.
Invest Fair
Invest Fair is an event where pharmaceuticals, bio, and healthcare companies that are advancing into the global market and developing new drugs introduce their superior technology and investors to the companies’ vision and strategy. Along with online hosting, it maintains its attendance by impressive lineups of 24 companies such as GC Greencross, Celltrion, Tium BIO, and ABL Bio.
Job Fair
Aiming to place its main objective in recruiting talented individuals amongst undergraduates and postgraduates searching for job vacancies in bio industry, companies participating in Job Fair will share their success tips in various fields. Amid current bleak jobs pictures, about 30 companies are attending with 150+ job openings.
Lastly, BIO KOREA remains committed to amplifying the industry’s efforts to develop solutions for patients. In response to the COVID-19 pandemic, the special sessions dealing with its diagnostic kits, therapeutics and vaccines, also sharing the cooperation among the governments, industries are prepared. Jerom Kim from IVI will deliver the Keynote speech for the COVID-19 special session.
For more information, visit BIO KOREA’s Official Website: www.biokorea.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005997/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom